Whalesbook
Mankind Pharma ke results dekh kar lagta hai company sahi track par hai. Unke strategic moves ka fayda dikh raha hai!
Profit mein zabardast izafa
Mankind Pharma ka net profit Q4 mein 30% badh kar ₹554 crore ho gaya, jo pichhle saal isi time ₹425 crore tha. Total revenue 11.8% badh kar ₹3,443 crore tak pahunch gaya 31 March 2026 ko khatam hone wale quarter mein. Company ke EBITDA margins bhi 27% tak pahunch gaye, jo pehle 22.2% the. Operating income 36.1% badh kar ₹930 crore ho gaya. Stock bhi pichhle ek mahine mein 17.3% badha hai aur ₹2,492.60 ke aas paas trade kar raha hai.
Domestic market aur acquisitions ka kamaal
Company ka domestic formulations business toh dhamakedar return kar raha hai. March mein sales growth 11.5% rahi, jo Indian pharma market ke average 10.6% se zyada hai. Cardiac aur anti-diabetes jaise chronic segments se achhi sales aa rahi hain, jo ab domestic sales ka 40% hissa hain. Bharat Serums and Vaccines ka acquisition bhi achha perform kar raha hai, jisse company ka specialty portfolio aur mazboot hua hai.
Valuation aur risks par bhi nazar rakhein
Itne acche results ke bawajood, Mankind Pharma ka valuation thoda high lag raha hai. Iska P/E ratio lagbhag 57.53x hai, jo industry median 22.01x se kaafi upar hai. Iska matlab hai ki future growth toh stock price mein already factored in hai, toh zyada upside kam ho sakta hai. International business thoda slow hai geopolitical issues ki wajah se. Aur 97% revenue India se aane ke karan market concentration ka risk bhi hai.
Aage kya?
Mankind Pharma lagta hai aage bhi grow karta rahega, kyunki domestic market mein pakad mazboot hai aur strategies sahi chal rahi hain. Chronic therapies par focus aur acquisitions ka fayda milta rahega. Par investors ko high valuation aur international market volatility ke risks dhyan mein rakhne chahiye. Company ne apni subsidiary Mankind Medicare Private Limited mein ₹500 crore tak invest karne ka bhi approval diya hai, jo aage expansion ke plans dikhata hai.